The members of the Antimicrobial Theme have been making significant contributions in the fight against antimicrobial resistance (AMR) through their prolific publication record. On average, they publish over 50 articles annually in prestigious academic journals, highlighting key advancements in tackling AMR. In the past few years, their research has yielded remarkable results, as evidenced by a selection of important publications and patents. These publications serve as a testament to the expertise and dedication of the Antimicrobial Theme members, and their invaluable contributions are instrumental in advancing our understanding of AMR and shaping effective strategies to combat this global threat.

Professor Miraz Rahman

1. Picconi, P., Mark Sutton, J., Hind, C. K., & Rahman, M.(2022). Covalent DNA Binding Is Essential for Gram-Negative Antibacterial Activity of Broad Spectrum Pyrrolobenzodiazepines. Antibiotics, 1-10. [1770].
2. Evans, L., Kotar, A., Valentini, M., Filloux, A., Jamshidi, S., Plavec, J., Rahman, M., & Vilar, R. (2022). Identification and characterisation of G-quadruplex DNA-forming sequences in the Pseudomonas aeruginosa genome. RSC Chemical Biology. https://doi.org/10.1039/d2cb00205a
3. Joseph, A. M., Nahar, K., Daw, S., Hasan, M., Lo, R., Le, T., Rahman, M., & Badrinarayanan, A. (2022). Mechanistic insight into the repair of C8-linked pyrrolobenzodiazepine monomer-mediated DNA damage. RSC Medicinal Chemistry, 32(2), 1-13. https://doi.org/10.1039/d2md00194b
4. Al-Adhami, T., Matsongos, C., Jamshidi, S., Hind, C. K., Clifford, M., Sutton, M., & Rahman, M.(Accepted/In press). Synthesis, Microbiological Evaluation and Structure Activity Relationship Analysis of Linezolid Analogues with Different C5-acylamino Substituents.  . Bioorganic and Medicinal Chemistry, 49, 1-13. [116397].
5. Chen, Y., Hamad, A., Khan, M., Jamshidi, S., Saeed, N., Clifford, M., Hind, C. K., Sutton, J. M., & Rahman, M.(2021). Schiff bases of sulphonamides as a new class of antifungal agent against multidrug-resistant Candida auris. MicrobiologyOpen, 10(4), 1-8. [e1218]. https://doi.org/10.1002/mbo3.1218
6. Picconi, P., Hind, C. K., Nahar, K. S., Jamshidi, S., Di Maggio, L., Saeed, N., Evans, B., Solomons, J., Wand, M. E., Mark Sutton, J., & Rahman, K. M.(2020). New broad-spectrum antibiotics containing a pyrrolobenzodiazepine ring with activity against multidrug resistant Gram-negative bacteria. Journal of Medicinal Chemistry, 63(13), 6941–6958. https://doi.org/10.1021/acs.jmedchem.0c00328
7. Picconi, P., Jeeves, R., Jamshidi, S., Nahar, K. S., Laws, M. B., Moon, C., Bacon, J., & Rahman, K. M.(2019). Noncytotoxic Pyrrolobenzodiazepine-Ciprofloxacin Conjugate with Activity against Mycobacterium tuberculosis: Ciprofloxacin Conjugate with Activity against Mycobacterium tuberculosis. ACS Omega, 4(25), 20873-20881. [acsomega.9b00834]. https://doi.org/10.1021/acsomega.9b00834
8. Laws, M. B., Shaaban, A., & Rahman, K. M.(2019). Antibiotic Resistance Breakers: Current Approaches and Future Directions. Fems Microbiology Reviews, 43(5), 490-516. https://doi.org/10.1093/femsre/fuz014
9. C8-Linked Pyrrolobenzodiazepine Monomers with Inverted Building Blocks Show Selective Activity against Multidrug Resistant Gram-Positive BacteriaAndriollo, P., Hind, C. K., Picconi, P., Nahar, K., Jamshidi, S., Varsha, A., Clifford, M., Sutton, J. M. & Rahman, M., 9 Feb 2018, In: ACS Infectious Disease.4, 2, 158–174 17 p.
10. Triaryl Benzimidazoles as a New Class of Antibacterial Agents against Resistant Pathogenic Microorganisms Picconi, P., Hind, C., Jamshidi, S., Nahar, K., Clifford, M., Wand, M. E., Sutton, J. M. & Rahman, K. M., 27 Jul 2017, In: Journal of Medicinal Chemistry.60, 14, 6045-6059 15 p.

For the full list of publications for Professor Miraz Rahman, please visit the PURE Portal

---

Professor Mark Sutton

1.  Allen, C., Turner, C., Kalsi, S., Jamieson, D., Li, Y., Morgan, H., & Sutton, J. M. (2020). Development of a rapid phenotypic test on a microfluidic device for carbapenemase detection using the chromogenic compound nitrocefin. Diagn Microbiol Infect Dis, 96(4), 114926. https://doi.org/10.1016/j.diagmicrobio.2019.114926
2. Di Blasio, S., Clarke, M., Hind, C. K., Asai, M., Laurence, L., Benvenuti, A., Hassan, M., Semenya, D., Man, D. K., Horrocks, V., Manzo, G., Van Der Lith, S., Lam, C., Gentile, E., Annette, C., Bosse, J., Li, Y., Panaretou, B., Langford, P. R., Robertson, B. D., Lam, J. K. W., Sutton, J. M., McArthur, M., & Mason, A. J. (2023). Bolaamphiphile Analogues of 12-bis-THA Cl(2) Are Potent Antimicrobial Therapeutics with Distinct Mechanisms of Action against Bacterial, Mycobacterial, and Fungal Pathogens. mSphere, 8(1), e0050822. https://doi.org/10.1128/msphere.00508-22
3. Fields, F. R., Manzo, G., Hind, C. K., Janardhanan, J., Foik, I. P., Carmo Silva, P. D., Balsara, R. D., Clifford, M., Vu, H. M., Ross, J. N., Kalwajtys, V. R., Gonzalez, A. J., Bui, T. T., Ploplis, V. A., Castellino, F. J., Siryaporn, A., Chang, M., Sutton, J. M., Mason, A. J., & Lee, S. (2020). Synthetic Antimicrobial Peptide Tuning Permits Membrane Disruption and Interpeptide Synergy. ACS Pharmacol Transl Sci, 3(3), 418-424. https://doi.org/10.1021/acsptsci.0c00001
4. Hamad, A., Chen, Y., Khan, M. A., Jamshidi, S., Saeed, N., Clifford, M., Hind, C., Sutton, J. M., & Rahman, K. M. (2021). Schiff bases of sulphonamides as a new class of antifungal agent against multidrug-resistant Candida auris. Microbiologyopen, 10(4), e1218. https://doi.org/10.1002/mbo3.1218
5. Hind, C. K., Dowson, C. G., Sutton, J. M., Jackson, T., Clifford, M., Garner, R. C., & Czaplewski, L. (2019). Evaluation of a Library of FDA-Approved Drugs for Their Ability To Potentiate Antibiotics against Multidrug-Resistant Gram-Negative Pathogens. Antimicrob Agents Chemother, 63(8). https://doi.org/10.1128/AAC.00769-19
6. Horrocks, V., Hind, C. K., Wand, M. E., Fady, P. E., Chan, J., Hopkins, J. C., Houston, G. L., Tribe, R. M., Sutton, J. M., & Mason, A. J. (2022). Nuclear Magnetic Resonance Metabolomics of Symbioses between Bacterial Vaginosis-Associated Bacteria. mSphere, 7(3), e0016622. https://doi.org/10.1128/msphere.00166-22
7. Impey, R. E., Lee, M., Hawkins, D. A., Sutton, J. M., Panjikar, S., Perugini, M. A., & Soares da Costa, T. P. (2020). Mis-annotations of a promising antibiotic target in high-priority gram-negative pathogens. FEBS Lett, 594(9), 1453-1463. https://doi.org/10.1002/1873-3468.13733
8. Impey, R. E., Panjikar, S., Hall, C. J., Bock, L. J., Sutton, J. M., Perugini, M. A., & Soares da Costa, T. P. (2020). Identification of two dihydrodipicolinate synthase isoforms from Pseudomonas aeruginosa that differ in allosteric regulation. FEBS J, 287(2), 386-400. https://doi.org/10.1111/febs.15014
9. Laws, M., Hind, C., Favaron, A., Jamshidi, S., Evans, B., Clifford, M., Sutton, J. M., & Rahman, K. M. (2020). N1-Benzofused Modification of Fluoroquinolones Reduces Activity Against Gram-Negative Bacteria. ACS Omega, 5(21), 11923-11934. https://doi.org/10.1021/acsomega.9b03910
10. Manzo, G., Hind, C. K., Ferguson, P. M., Amison, R. T., Hodgson-Casson, A. C., Ciazynska, K. A., Weller, B. J., Clarke, M., Lam, C., Man, R. C. H., Shaughnessy, B. G. O., Clifford, M., Bui, T. T., Drake, A. F., Atkinson, R. A., Lam, J. K. W., Pitchford, S. C., Page, C. P., Phoenix, D. A., Lorenz, C. D., Sutton, J. M., & Mason, A. J. (2020). A pleurocidin analogue with greater conformational flexibility, enhanced antimicrobial potency and in vivo therapeutic efficacy. Commun Biol, 3(1), 697. https://doi.org/10.1038/s42003-020-01420-3

For the full list of publications for Professor Mark Sutton, please visit the PURE Portal

---

Richard Amison

1. Arkless, K. L., Pan, D., Shankar‐Hari, M., Amison, R. T., Page, C. P., Rahman, K. M., & Pitchford, S. C.(2023). Stimulation of platelet P2Y₁ receptors by different endogenous nucleotides leads to functional selectivity via biased signalling. British journal of pharmacology. https://doi.org/10.1111/bph.16039
2. Arkless, K., Amison, R., Shankar-Hari, M., Page, C., & Pitchford, S.(2021). Stimulation of the Platelet P2Y(1) Receptor by Endogenous Agonists Leads to a Dichotomy in Platelet Function. British journal of pharmacology, 178(2), 381-382.
3. Manzo, G., Hind, C. K., Ferguson, P., Amison, R., Hodgson-Casson, A., Ciazynska, K., Weller, B., Clarke, M., Lam, C., Man, R., O'Shaughnessy, B., Clifford, M., Bui, T., Drake, A., Atkinson, A., Lam, J., Pitchford, S., Page, C., Phoenix, D., ... Mason, J.(2020). A Pleurocidin Analogue with Greater Conformational Flexibility, Enhanced Antimicrobial Potency and in vivo Therapeutic Efficacy. Communications Biology, 3(1), [697]. https://doi.org/10.1038/s42003-020-01420-3
4. Arnold, S., Shah, S. A., Cleary, S. J., O'shaughnessy, B. G., Amison, R. T., Arkless, K., Page, C. P., & Pitchford, S. C.(2020). Red Blood Cells Elicit Platelet-Dependent Neutrophil Recruitment into Lung Airspaces. Shock, 56(2). https://doi.org/10.1097/SHK.0000000000001705
5. Cleary, S. J., Pitchford, S. C., Amison, R. T., Carrington, R., Robaina Cabrera, C. L., Magnen, M., Looney, M. R., Gray, E., & Page, C. P.(2020). Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. British Journal of Pharmacology, 177(21), 4851-4865. https://doi.org/10.1111/bph.15143
6. Amison, R. T., Faure, M-E. Y. L., O'Shaughnessy, B. G., Bruce, K., Hu, Y., Coates, A., & Page, C. P.(2020). The small quinolone derived compound HT61 enhances the effect of tobramycin against Pseudomonas aeruginosa in vitro and in vivo. Pulmonary pharmacology & therapeutics, 61, [101884]. https://doi.org/10.1016/j.pupt.2019.101884
7. Cleary, S. J., Hobbs, C., Amison, R., Arnold, S., O'Shaughnessy, B. G., Lefrançais, E., Mallavia, B., Looney, M. R., Page, C. P., & Pitchford, S. C.(2019). LPS-Induced Lung Platelet Recruitment Occurs Independently from Neutrophils, PSGL-1, and P-selectin. American Journal of Respiratory Cell and Molecular Biology, 61(2), 232-243. https://doi.org/10.1165/rcmb.2018-0182OC
8. Pitchford, S., Cleary, S., Arkless, K., & Amison, R.(2019). Pharmacological strategies for targeting platelet activation in asthma. Current Opinion in Pharmacology, 46, 55-64. https://doi.org/10.1016/j.coph.2019.03.012

For the full list of publications for Richard Amison, please visit the PURE Portal

---

Ken Bruce

1. Zain, N. M. M., ter Linden, D., Lilley, A. K., Royall, P. G., Tsoka, S., Bruce, K. D., Mason, A. J., Hatton, G. B., Allen, E., Goldenberg, S. D., & Forbes, B.(2022). Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards. Journal of Controlled Release, 350, 324-331. https://doi.org/10.1016/j.jconrel.2022.08.012
2. Webb, K., Zain, N. M. M., Stewart, I., Fogarty, A., Nash, E. F., Whitehouse, J. L., Smyth, A. R., Lilley, A. K., Knox, A., Williams, P., Cámara, M., Bruce, K., & Barr, H. L. (2022). Porphyromonas pasteri and Prevotella nanceiensis in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosis. Journal of medical microbiology, 71(2), [001481]. https://doi.org/10.1099/jmm.0.001481
3. Patel, V. C., Lee, S., McPhail, M. J. W., Zamalloa, A., Witherden, E., Stoy, S., Vijay, G. M., Huang, X., Gencer, S., Coen, M., Tranah, T., Wendon, J., Bruce, K., Ehrlich, D., Edwards, L. A., Shoaie, S., & Shawcross, D. L.(2022). Rifaximin reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial. Journal of Hepatology, 76(2), 332-342. https://doi.org/10.1016/j.jhep.2021.09.010
4. Zain, N. M. M., Webb, K., Stewart, I., Halliday, N., Barrett, D. A., Nash, E. F., Whitehouse, J. L., Honeybourne, D., Smyth, A. R., Forrester, D. L., Knox, A. J., Williams, P., Fogarty, A., Cámara, M., Bruce, K. D., & Barr, H. L. (2021). 2-Alkyl-4-quinolone quorum sensing molecules are biomarkers for culture-independent Pseudomonas aeruginosa burden in adults with cystic fibrosis. Journal of Medical Microbiology, 70(10), [001420]. https://doi.org/10.1099/jmm.0.001420
5. Azim, A., Green, B., Lau, L., Rupani, H., Jayasekera, N., Bruce, K., & Howarth, P. (2021). Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma. Allergy: European Journal of Allergy and Clinical Immunology, 76(7), 2070-2078. https://doi.org/10.1111/all.14732
6. Webb, K., Cámara, M., Zain, N. M. M., Halliday, N., Bruce, K. D., Nash, E. F., Whitehouse, J. L., Knox, A., Forrester, D., Smyth, A. R., Williams, P., Fogarty, A., & Barr, H. L. (Accepted/In press). Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis. Journal Of Cystic Fibrosis. https://doi.org/10.1016/j.jcf.2021.08.030
7. Martin, M. J., Zain, N. M. M., Hearson, G., Rivett, D. W., Koller, G., Wooldridge, D. J., Rose, G., Gharbia, S. E., Forbes, B., Bruce, K. D., & Harrison, T. W. (2020). The airways microbiome of individuals with asthma treated with high and low doses of inhaled corticosteroids. PLoS ONE, 15(12 December), [e0244681]. https://doi.org/10.1371/journal.pone.0244681
8. Koller, G., Foschi, F., Witherden, L., Mitchell, P., Bruce, K., & Mannocci, F.(2020). Amoebae in Chronic, Polymicrobial Endodontic Infections Are Associated with Altered Microbial Communities of Increased Virulence. Journal of Clinical Medicine, Clin. Med. 2020, 9(11), 3700; .
9. Vandera, K-K. A., Picconi, P., Valero, M., González-Gaitano, G., Woods, A., Zain, N. M., Bruce, K., Clifton, L. A., Skoda, M. W. A., Rahman, K. M., Harvey, R. D., & Dreiss, C.(2020). Antibiotic-in-cyclodextrin-in-liposomes: formulation development and interactions with model bacterial membranes. Molecular Pharmaceutics, 17(7), 2354-2369. https://doi.org/10.1021/acs.molpharmaceut.0c00096
10. Cuthbertson, L., Walker, A. W., Oliver, A. E., Rogers, G. B., Rivett, D. W., Hampton, T. H., Ashare, A., Elborn, J. S., De Soyza, A., Carroll, M. P., Hoffman, L. R., Lanyon, C., Moskowitz, S. M., O'Toole, G. A., Parkhill, J., Planet, P. J., Teneback, C. C., Tunney, M. M., Zuckerman, J. B., ... Van Der Gast, C. J. (2020). Lung function and microbiota diversity in cystic fibrosis. Microbiome, 8(1), [45]. https://doi.org/10.1186/s40168-020-00810-3

For the full list of publications for Ken Bruce, please visit the PURE Portal

---

Kourosh Ebrahimi

1. Vaughan-Jackson, A., Stodolak, S., Ebrahimi, K. H., Johnson, E., Reardon, P. K., Dupont, M., Zhang, S., McCullagh, J. S. O., & James, W. S. (2022). Density dependent regulation of inflammatory responses in macrophages. Frontiers in Immunology, 13, [895488]. https://doi.org/10.3389/fimmu.2022.895488
2. Ji, Y., Wei, L., Da, A., Stark, H., Hagedoorn, P. L., Ciofi-Baffoni, S., Cowley, S. A., Louro, R. O., Todorovic, S., Mroginski, M. A., Nicolet, Y., Roessler, M. M., Le Brun, N. E., Piccioli, M., James, W. S., Hagen, W. R., & Ebrahimi, K. H.(2022). Radical-SAM dependent nucleotide dehydratase (SAND), rectification of the names of an ancient iron-sulfur enzyme using NC-IUBMB recommendations. Frontiers in Molecular Biosciences, 9, [1032220]. https://doi.org/10.3389/fmolb.2022.1032220
3. Honarmand Ebrahimi, K., Ciofi-Baffoni, S., Hagedoorn, P. L., Nicolet, Y., Le Brun, N. E., Hagen, W. R., & Armstrong, F. A. (2022). Iron–sulfur clusters as inhibitors and catalysts of viral replication. Nature Chemistry, 14(3), 253-266. https://doi.org/10.1038/s41557-021-00882-0
4. Quinn, T. M., Gaughan, E. E., Bruce, A., Antonelli, J., O'Connor, R., Li, F., McNamara, S., Koch, O., MacKintosh, C., Dockrell, D., Walsh, T., Blyth, K. G., Church, C., Schwarze, J., Boz, C., Valanciute, A., Burgess, M., Emanuel, P., Mills, B., ... Dhaliwal, K. (2022). Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: Phase 1b/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics. EBioMedicine, 76, [103856]. https://doi.org/10.1016/j.ebiom.2022.103856
5. Dragelj, J., Mroginski, M. A., & H. Ebrahimi, K.(2021). Hidden in Plain Sight: Natural Products of Commensal Microbiota as an Environmental Selection Pressure for the Rise of New Variants of SARS‐CoV‐2. Chembiochem : a European journal of chemical biology, 22(20), 2946-2950. https://doi.org/10.1002/cbic.202100346
6. Ebrahimi, K., & McCullagh, J. S. (2021). A lipidomic view of SARS-CoV-2. Bioscience Reports, 41(8), [BSR20210953]. https://doi.org/10.1042/BSR20210953
7. Vaughan-Jackson, A., Stodolak, S., H. Ebrahimi, K., Browne, C., K. Reardon, P., Gilbert-Jaramillo, J., A. Cowley, S., & James, W. (2021). Differentiation of human induced pluripotent stem cells to authentic macrophages using a defined, serum-free, open-source medium. Stem Cell Reports, 16(7), 1735-1748. https://doi.org/10.1016/j.stemcr.2021.05.018
8. Ebrahimi, K., Gilbert-Jaramillo, J., S. James, W., & S. O. McCullagh, J. (2021). Interferon-stimulated gene products as regulators of central carbon metabolism. The FEBS journal, 288(12), 3715-3726. https://doi.org/10.1111/febs.15625
9. Ebrahimi, K.(2021). Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19. Chembiochem : a European journal of chemical biology, 22(8), 1371-1378. https://doi.org/10.1002/cbic.202000728
10. Rack, J. G. M., Liu, Q., Zorzini, V., Voorneveld, J., Ariza, A., H. Ebrahimi, K., M. Reber, J., C. Krassnig, S., Ahel, D., van der Marel, G. A., Mangerich, A., S. O. McCullagh, J., V. Filippov, D., & Ahel, I. (2021). Mechanistic insights into the three steps of poly(ADP-ribosylation) reversal. Nature Communications, 12(1), [4581]. https://doi.org/10.1038/s41467-021-24723-3

For the full list of publications for Kourosh Ebrahimi, please visit the PURE Portal

---

Ben Forbes

1. Wingrove, J., O'Daly, O., De Lara Rubio, A., Hill, S., Swedroska, M., Forbes, B., Amiel, S., & Zelaya, F.(2022). The influence of insulin on anticipation and consummatory reward to food intake: A functional imaging study on healthy normal weight and overweight subjects employing intranasal insulin delivery. Human Brain Mapping, 43(18), 5432-5451. https://doi.org/10.1002/hbm.26019
2. Zain, N. M. M., ter Linden, D., Lilley, A. K., Royall, P. G., Tsoka, S., Bruce, K. D., Mason, A. J., Hatton, G. B., Allen, E., Goldenberg, S. D., & Forbes, B.(2022). Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards. Journal of Controlled Release, 350, 324-331. https://doi.org/10.1016/j.jconrel.2022.08.012
3. Carserides, C., Smith, K., Zinicola, M., Kumar, A., Swedrowska, M., Scala, C., Cameron, G., Riches, Z., Iannelli, F., Pozzi, G., Hold, G. L., Forbes, B., Kelly, C., & Hijazi, K. (2022). Comprehensive Study of Antiretroviral Drug Permeability at the Cervicovaginal Mucosa via an In Vitro Model. Pharmaceutics, 14(9), [1938]. https://doi.org/10.3390/pharmaceutics14091938
4. Niaz, S., Forbes, B., & Raimi-Abraham, B. T.(2022). Exploiting Endocytosis for Non-Spherical Nanoparticle Cellular Uptake. Nanomanufacturing, 2(1), 1-16. https://doi.org/10.3390/nanomanufacturing2010001
5. Terakosolphan, W., Altharawi, A., Poonprasartporn, A., Harvey, R. D., Forbes, B. & Chan, K. L. A.(2021). In vitro Fourier transform infrared spectroscopic study of the effect of glycerol on the uptake of beclomethasone dipropionate in living respiratory cells. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 609, [121118]. https://doi.org/10.1016/j.ijpharm.2021.121118
6. Sonvico, F., Chierici, V., Varacca, G., Quarta, E., D’angelo, D., Forbes, B., & Buttini, F. (2021). Respicell^tm: An innovative dissolution apparatus for inhaled products. Pharmaceutics, 13(10), [1541]. https://doi.org/10.3390/pharmaceutics13101541
7. Lee, D. D. H., Cardinale, D., Terakosolphan, W., Sornsute, A., Radhakrishnan, P., Coppel, J., Smith, C. M., Satyanarayana, S., Forbes, B., & O'Callaghan, C. (2021). Fluticasone Particles Bind to Motile Respiratory Cilia: A Mechanism for Enhanced Lung and Systemic Exposure?Journal of Aerosol Medicine and Pulmonary Drug Delivery, 34(3), 181-188. https://doi.org/10.1089/jamp.2020.1598
8. Enlo-Scott, Z., Bäckström, E., Mudway, I., & Forbes, B.(2021). Drug metabolism in the lungs: opportunities for optimising inhaled medicines. Expert Opinion On Drug Metabolism & Toxicology, 17(5), 611-625. https://doi.org/10.1080/17425255.2021.1908262
9. Enlo-Scott, Z., Swedrowska, M., & Forbes, B.(2021). Epithelial permeability and drug absorption in the lungs. In Inhaled Medicines: Optimizing Development through Integration of In Silico, In Vitro and In Vivo Approaches (pp. 267-299). Academic Press. https://doi.org/10.1016/B978-0-12-814974-4.00004-3
10. Swedrowska, M., Ingham, S., Tomlin, S., & Forbes, B.(2021). Recommendations for crushing Circadin® (melatonin) tablets for safe and reliable delivery via pediatric nasogastric tubes. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 594, [120151]. https://doi.org/10.1016/j.ijpharm.2020.120151

For the full list of publications for Ben Forbes, please visit the PURE Portal

---

Professor Stuart Jones

1. Benaouda, F., Inacio, R., Lim, C. H., Park, H., Pitcher, T., Alhnan, M. A., Aly, M. M. S., Al-jamal, K. T., Chan, K-L., Gala, R. P., Sebastia-saez, D., Cui, L., Chen, T., Keeble, J., & Jones, S. A.(2022). Needleless administration of advanced therapies into the skin via the appendages using a hypobaric patch. Proceedings of the National Academy of Sciences of the United States of America, 119(18), e2120340119. [e2120340119]. https://doi.org/10.1073/pnas.2120340119
2. Mohamed Sofian, Z., Harun, N., Mahat, M. M., Nor Hashim, N. A., & Jones, S. A.(2021). Investigating how amine structure influences drug-amine ion-pair formation and uptake via the polyamine transporter in A549 lung cells. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 168, 53-61. https://doi.org/10.1016/j.ejpb.2021.08.003
3. Sebastia-Saez, D., Benaouda, F., Lim, C. H., Lian, G., Jones, S., Chen, T., & Cui, L. (2021). Numerical analysis of the strain distribution in skin domes formed upon the application of hypobaric pressure. SKIN RESEARCH AND TECHNOLOGY, 27(5), 948-958. https://doi.org/10.1111/srt.13047
4. Saleh, M., Lawrence, K., Jones, S., & Young, A.(2021). The Photoprotective Properties of α-Tocopherol Phosphate Against Long-Wave UVA1 (385 nm) Radiation in Keratinocytes in Vitro. Scientific Reports. https://www.researchsquare.com/article/rs-275304/v1
5. Wan, M., Patel, A., Patel, J., Greta, R., Jones, S., & Shroff, R. (2021). Quality and use of unlicensed vitamin D preparations in primary care in England: Retrospective review of national prescription data and laboratory analysis. British Journal of Clinical Pharmacology, 87(3), 1338-1346. https://doi.org/10.1111/bcp.14521
6. Saleh, M. M., Woods, A., Harvey, R. D., Young, A. R., & Jones, S. A.(2021). Nanomaterials fusing with the skin: Alpha-tocopherol phosphate delivery into the viable epidermis to protect against ultraviolet radiation damage. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 594, [120000]. https://doi.org/10.1016/j.ijpharm.2020.120000
7. Jones, S., Sofian, Z. M., Forbes, B., Al-Jamal, K., Benaouda, F., Royall, P., Wang, J., Luo, Y. M., Farag, D., & Rahman, M.(2020). A Cyclodextrin‐Stabilized Spermine‐Tagged Drug Triplex that Targets Theophylline to the Lungs Selectively in Respiratory Emergency. Advanced Therapeutics.
8. Harper, R. A., Petersen, L., Saleh, M., Proctor, G. B., Carpenter, G. H., Gambogi, R., Hider, R., & Jones, S. A.(2019). Targeting macrophages and their recruitment in the oral cavity using swellable (+) alpha tocopheryl phosphate nanostructures. Nanomedicine : nanotechnology, biology, and medicine, 21, [102010]. https://doi.org/10.1016/j.nano.2019.04.013
9. Chen, H., Mansfield, E. D. H., Woods, A., Khutoryanskiy, V. V., Forbes, B., & Jones, S. A.(2019). Mucus penetrating properties of soft, distensible lipid nanocapsules. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 139, 76-84. https://doi.org/10.1016/j.ejpb.2019.02.020
10. Sofian, Z. M., Wang, J. T. W., Yuan, L., Royall, P., Forbes, B., Barlow, D. J., Page, C., Al-Jamal, K. T., Jones, S., & Benaouda, F.(2019). CYCLODEXTRIN-STABILISED ION-PAIR COMPLEXES ENHANCE DRUG LUNG UPTAKE VIA THE POLYAMINE TRANSPORTER. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 32(2), A11-A11.

For the full list of publications for Professor Stuart Jones, please visit the PURE Portal

---

Paul Long

1. Qin, X., Costa-Silva, T. A., Pessoa, A., & Long, P. F.(2023). A scoping review to compare and contrast quality assurance aspects of L-asparaginase biosimilars. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 632, [122523]. https://doi.org/10.1016/j.ijpharm.2022.122523
2. Hartigan, A., Jaimes-Becerra, A., Okamura, B., Doonan, L. B., Ward, M., Marques, A. C., & Long, P. F.(2021). Recruitment of toxin-like proteins with ancestral venom function supports endoparasitic lifestyles of Myxozoa. PeerJ, 9, [e11208]. https://doi.org/10.7717/peerj.11208
3. da Silva, L. S., Doonan, L. B., Pessoa, A., de Oliveira, M. A., & Long, P. F.(2021). Structural and functional diversity of asparaginases: Overview and recommendations for a revised nomenclature. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2127
4. Okamura, B., Hartigan, A., Long, P. F., Ruggeri, P., Smith-Easter, K., & Schooley, J. D. (2020). Epidemiology of Polypodium hydriforme in American Paddlefish. JOURNAL OF FISH DISEASES, 43(9), 979-989. https://doi.org/10.1111/jfd.13202
5. Kitahara, M. V., Jaimes-Becerra, A., Gamero-Mora, E., Padilla, G., Doonan, L. B., Ward, M., Marques, A. C., Morandini, A. C., & Long, P. F.(2020). Reciprocal transplantation of the heterotrophic coral Tubastraea coccinea (Scleractinia: Dendrophylliidae) between distinct habitats did not alter its venom toxin composition. Ecology and Evolution. https://doi.org/10.1002/ece3.5959
6. Simas, R. G., Krebs Kleingesinds, E., Pessoa Junior, A., & Long, P. F.(Accepted/In press). An improved method for simple and accurate colorimetric determination of l-asparaginase enzyme activity using Nessler's reagent. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY. https://doi.org/10.1002/jctb.6651
7. Geraldes, V., de Medeiros, L. S., Lima, S. T., Alvarenga, D. O., Gacesa, R., Long, P. F., Fiore, M. F., & Pinto, E. (2020). Genetic and biochemical evidence for redundant pathways leading to mycosporine-like amino acid biosynthesis in the cyanobacterium sphaerospermopsis torques-reginae ITEP-024. Algae, 35(2), 177-187. https://doi.org/10.4490/algae.2020.35.5.19
8. Jaimes-Becerra, A., Gacesa, R., Doonan, L. B., Hartigan, A., Marques, A. C., Okamura, B., & Long, P. F.(2019). "beyond Primary Sequence" - Proteomic Data Reveal Complex Toxins in Cnidarian Venoms. INTEGRATIVE AND COMPARATIVE BIOLOGY, 59(4), 777-785. https://doi.org/10.1093/icb/icz106
9. Okamura, B., Long, P. F., & Mydlarz, L. D. (2019). Chemical Responses to the Biotic and Abiotic Environment by Early Diverging Metazoans Revealed in the Post-Genomic Age. INTEGRATIVE AND COMPARATIVE BIOLOGY, 59(4), 731-738. https://doi.org/10.1093/icb/icz125
10. Doonan, L. B., Hartigan, A., Okamura, B., & Long, P. F.(2019). Stress-Free Evolution: The Nrf-Coordinated Oxidative Stress Response in Early Diverging Metazoans. INTEGRATIVE AND COMPARATIVE BIOLOGY, 59(4), 799-810. https://doi.org/10.1093/icb/icz055

For the full list of publications for Paul Long, please visit the PURE Portal

---

Professor James Mason

1. Abuhelal, S., Centelles, M., Wright, M., Mason, J., & Thanou, M.(2023). Development of Cationic Lipid LAH4-L1 siRNA Complexes for Focused Ultrasound Enhanced Tumor Uptake. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.2c00909
2. Di Blasio, S., Clarke, M., Hind, C. K., Asai, M., Laurence, L., Benvenuti, A., Hassan, M., Semenya, M. M. D., Man, D. K-W., Horrocks, V., Manzo, G., Van Der Lith, S., Gentile, E., Lam, C., Annette, C., Bosse, J., Li, Y., Panaretou, B., Langford, P., ... Mason, J.(2022). Bolaamphiphile analogues of 12-bis-THA Cl2 are potent antimicrobial therapeutics with distinct mechanisms of action against bacterial, mycobacterial, and fungal pathogens. mSphere. https://journals.asm.org/doi/10.1128/msphere.00508-22
3. Zain, N. M. M., ter Linden, D., Lilley, A. K., Royall, P. G., Tsoka, S., Bruce, K. D., Mason, A. J., Hatton, G. B., Allen, E., Goldenberg, S. D., & Forbes, B.(2022). Design and manufacture of a lyophilised faecal microbiota capsule formulation to GMP standards. Journal of Controlled Release, 350, 324-331. https://doi.org/10.1016/j.jconrel.2022.08.012
4. Horrocks, V., Hind, C. K., Wand, M. E., Fady, P-E., Chan, J., Hopkins, J., Houston, G., Tribe, R., Sutton, J., & Mason, J.(2022). Nuclear magnetic resonance metabolomics of symbioses between bacterial vaginosis associated bacteria. mSphere, 7(3), e0016622. https://doi.org/10.1128/msphere.00166-22
5. Mohd Zaki, A., Hadingham, A., Flaviani, F., Haque, Y., Mi, J. D., Finucane, D., Dalla Valle, G., Mason, A. J., Saqi, M., Gibbons, D. L., & Tribe, R. M.(2022). Neutrophils Dominate the Cervical Immune Cell Population in Pregnancy and Their Transcriptome Correlates With the Microbial Vaginal Environment. Frontiers in microbiology, 13, [904451]. https://doi.org/10.3389/fmicb.2022.904451
6. Ferguson, P., Clarke, M., Manzo, G., Hind, C. K., Clifford, M., Sutton, J., Lorenz, C., Phoenix, D., & Mason, J.(2022). Temporin B forms hetero-oligomers with Temporin L, modifies its membrane activity and increases the cooperativity of its antibacterial pharmacodynamic profile. Biochemistry, 61(11), 1029-1040. https://doi.org/10.1021/acs.biochem.1c00762
7. Ali, S., Dussouillez, C., Padilla, B., Frisch, B., Mason, J., & Kichler, A. (2021). Design of a new cell penetrating peptide for DNA, siRNA and mRNA delivery. JOURNAL OF GENE MEDICINE. https://doi.org/10.1002/jgm.3401
8. Bock, L. J., Ferguson, P., Clarke, M., Pumpitakkul, V., Wand, M. E., Fady, P-E., Allison, L., Fleck, R., Shepherd, M., Mason, J., & Sutton, J. M. (2021). Pseudomonas aeruginosa adapts to octenidine via a combination of efflux and membrane remodelling. Communications Biology, 4(1), [1058]. https://doi.org/10.1038/s42003-021-02566-4
9. Flaviani, F., Hezelgrave, N. L., Kanno, T., Prosdocimi, E. M., Chin-Smith, E., Ridout, A. E., von Maydell, D. K., Mistry, V., Wade, W. G., Shennan, A. H., Dimitrakopoulou, K., Seed, P. T., Mason, A. J., & Tribe, R. M.(2021). Cervicovaginal microbiota and metabolome predict preterm birth risk in an ethnically diverse cohort. JCI Insight, 6(16), [e149257]. https://doi.org/10.1172/jci.insight.149257
10. Manzo, G., Gianfanti, F., Hind, C. K., Allison, L., Clarke, M., Hohenbichler, J., Limantoro, I., Martin, B., Do Carmo Silva, P., Ferguson, P., Hodgson-Casson, A., Fleck, R., Sutton, J. M., Phoenix, D., & Mason, J.(2021). Impacts of metabolism and organic acids on cell wall composition and Pseudomonas aeruginosa susceptibility to membrane active antimicrobials. ACS Infectious Disease, 7(8), 2310-2323. https://doi.org/10.1021/acsinfecdis.1c00002

For the full list of publications for Professor James Mason, please visit the PURE Portal

---

Professor Clive Page

1. Arkless, K. L., Pan, D., Shankar‐Hari, M., Amison, R. T., Page, C. P., Rahman, K. M., & Pitchford, S. C.(2023). Stimulation of platelet P2Y₁ receptors by different endogenous nucleotides leads to functional selectivity via biased signalling. British journal of pharmacology. https://doi.org/10.1111/bph.16039
2. Arnold, S., Watts, S., Kirkman, E., Page, C. P., Pitchford, S. C., & Albericio, F. (Ed.) (2022). Single and Multiplex Immunohistochemistry to Detect Platelets and Neutrophils in Rat and Porcine Tissues. Methods and Protocols, 5(5), 71. https://doi.org/10.3390/mps5050071
3. Cazzola, M., Page, C., Rogliani, P., Calzetta, L., & Matera, M. G. (2022). Dual bronchodilation for the treatment of COPD: From bench to bedside. British Journal of Clinical Pharmacology, 88(8), 3657-3673. https://doi.org/10.1111/bcp.15390
4. CHARTER Collaborative Research Group (2022). Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): Protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. British Journal of Clinical Pharmacology, 88(7), 3272-3287. https://doi.org/10.1111/bcp.15253
5. Rogliani, P., Page, C., & Calzetta, L. (2022). Prescribing the right therapy for the treatment of chronic cough: a critical focus on current and investigational options. Expert opinion on pharmacotherapy, 23(7), 741-744. https://doi.org/10.1080/14656566.2022.2047646
6. Calverley, P. M. A., Papi, A., Page, C., Rogliani, P., Dal Negro, R. W., Cazzola, M., Cicero, A. F., & Wedzicha, J. A. (2022). The Effect of Maintenance Treatment with Erdosteine on Exacerbation Treatment and Health Status in Patients with COPD: A Post-Hoc Analysis of the RESTORE Dataset. International Journal of COPD, 17, 1909-1920. https://doi.org/10.2147/COPD.S369804
7. Man, F., Nadkarni, S., Kanabar-Raivadera, V., Rodrigues e-Lacerda, R., Ferreira, S. G., Federici Canova, D., Perretti, M., Page, C., & Riffo Vasquez, Y.(Accepted/In press). "A peptide derived from chaperonin 60.1, IRL201104, inhibits LPS-induced acute lung inflammation": Effect of IRL201104 on lung inflammation. AMERICAN JOURNAL OF PHYSIOLOGY: LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, [10.1152/ajplung.00155.2021].
8. Robaina Cabrera, C. L., Keir-Rudman, S., Horniman, N., Clarkson, N., & Page, C.(2021). The anti-inflammatory effects of cannabidiol and cannabigerol alone, and in combination. Pulmonary Pharmacology and Therapeutics, 69, [102047]. https://doi.org/10.1016/j.pupt.2021.102047
9. Carrington, R., Jordan, S., Wong, Y. J., Pitchford, S. C., & Page, C. P.(2021). A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin. Journal of pharmacological and toxicological methods, 109, [107057]. https://doi.org/10.1016/j.vascn.2021.107057
10. Shah, S. A., Kanabar, V., Riffo-Vasquez, Y., Mohamed, Z., Cleary, S. J., Corrigan, C., James, A. L., Elliott, J. G., Shute, J. K., Page, C. P., & Pitchford, S. C.(2021). Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3. American Journal of Respiratory Cell and Molecular Biology, 64(5), 557–568. https://doi.org/10.1165/rcmb.2020-0425OC

For the full list of publications for Professor Clive Page, please visit the PURE Portal

---

Dr Barry Panaretou

1. Di Blasio, S., Clarke, M., Hind, C. K., Asai, M., Laurence, L., Benvenuti, A., Hassan, M., Semenya, M. M. D., Man, D. K-W., Horrocks, V., Manzo, G., Van Der Lith, S., Gentile, E., Lam, C., Annette, C., Bosse, J., Li, Y., Panaretou, B., Langford, P., ... Mason, J.(2022). Bolaamphiphile analogues of 12-bis-THA Cl2 are potent antimicrobial therapeutics with distinct mechanisms of action against bacterial, mycobacterial, and fungal pathogens. mSphere. https://journals.asm.org/doi/10.1128/msphere.00508-22
2. Prescott, T. A. K., Anaissi-Afonso, L., Fox, K. R., Maxwell, A., Panaretou, B., & Machín, F. (2022). A simplified and easy-to-use HIP HOP assay provides insights into chalcone antifungal mechanisms of action. FEBS Letters, 596(23), 3087-3102. https://doi.org/10.1002/1873-3468.14483
3. CAPSys Study Group (2022). ADAM8 signaling drives neutrophil migration and ARDS severity. JCI Insight, 7(3), [e149870]. https://doi.org/10.1172/jci.insight.149870
4. Woodford, M. R., Sager, R. A., Marris, E., Dunn, D. M., Blanden, A. R., Murphy, R. L., Rensing, N., Shapiro, O., Panaretou, B., Prodromou, C., Loh, S. N., Gutmann, D. H., Bourboulia, D., Bratslavsky, G., Wong, M., & Mollapour, M. (2017). Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients. The EMBO journal, 36(24), 3650-3665. https://doi.org/10.15252/embj.201796700
5. Prescott, T. A. K., & Panaretou, B.(2017). A Mini HIP HOP Assay Uncovers a Central Role for Copper and Zinc in the Antifungal Mode of Action of Allicin. JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY. https://doi.org/10.1021/acs.jafc.7b00250
6. Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors Woodford, M. R., Truman, A. W., Dunn, D. M., Jensen, S. M., Cotran, R., Bullard, R., Abouelleil, M., Beebe, K., Wolfgeher, D., Wierzbicki, S., Post, D. E., Caza, T., Tsutsumi, S., Panaretou, B., Kron, S. J., Trepel, J. B., Landas, S., Prodromou, C., Shapiro, O., Stetler-Stevenson, W. G., & 4 others, 2 Feb 2016, In: Cell Reports.14, 4, 872-84 13 p.
7. The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding Woodford, M. R., Dunn, D. M., Blanden, A. R., Capriotti, D., Loiselle, D., Prodromou, C., Panaretou, B., Hughes, P. F., Smith, A., Ackerman, W., Haystead, T. A., Loh, S. N., Bourboulia, D., Schmidt, L. S., Marston Linehan, W., Bratslavsky, G. & Mollapour, M., 29 Jun 2016, In: Nature Communications.7, 12037.
8. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors Mollapour, M., Bourboulia, D., Beebe, K., Woodford, M. R., Polier, S., Hoang, A., Chelluri, R., Li, Y., Guo, A., Lee, M-J., Fotooh-Abadi, E., Khan, S., Prince, T., Miyajima, N., Yoshida, S., Tsutsumi, S., Xu, W., Panaretou, B., Stetler-Stevenson, W. G., Bratslavsky, G., & 3 others, 23 Jan 2014, In: MOLECULAR CELL.53, 2, 317-329 13 p.
9. A yeast chemical genetics approach identifies the compound 3,4,5-trimethoxybenzyl isothiocyanate as a calcineurin inhibitor Prescott, T. A. K., Panaretou, B., Veitch, N. C. & Simmonds, M. S. J., 31 Jan 2014, In: FEBS Letters.588, 3, 455-458 4 p.
10. Yeast models for amyloid disease Panaretou, B.& Jones, G. W., 2014, In: Essays in Biochemistry. 56, 1, 85-97 13 p.

For the full list of publications for Dr Barry Panaretou, please visit the PURE Portal

---

Dr Simon Pitchford

1. Arkless, K. L., Pan, D., Shankar‐Hari, M., Amison, R. T., Page, C. P., Rahman, K. M., & Pitchford, S. C.(2023). Stimulation of platelet P2Y₁ receptors by different endogenous nucleotides leads to functional selectivity via biased signalling. British journal of pharmacology. https://doi.org/10.1111/bph.16039
2. Arnold, S., Watts, S., Kirkman, E., Page, C. P., Pitchford, S. C., & Albericio, F. (Ed.) (2022). Single and Multiplex Immunohistochemistry to Detect Platelets and Neutrophils in Rat and Porcine Tissues. Methods and Protocols, 5(5), 71. https://doi.org/10.3390/mps5050071
3. Pitchford, S., & Zanella, I. (2022). COVID-19 therapy, from lung disease to systemic disorder. Current Research in Pharmacology and Drug Discovery, 3, [100099]. https://doi.org/10.1016/j.crphar.2022.100099
4. Pantarelli, C., Pan, D., Chetwynd, S., Stark, A. K., Hornigold, K., Machin, P., Crossland, L., Cleary, S. J., Baker, M. J., Hampson, E., Mandel, A., Segonds-Pichon, A., Walker, R., Van t Veer, C., Riffo-Vasquez, Y., Okkenhaug, K., Pitchford, S., & Welch, H. C. E. (2021). The GPCR adaptor protein norbin suppresses the neutrophil-mediated immunity of mice to pneumococcal infection. Blood Advances, 5(16), 3076-3091. https://doi.org/10.1182/bloodadvances.2020002782
5. Carrington, R., Jordan, S., Wong, Y. J., Pitchford, S. C., & Page, C. P.(2021). A novel murine model of pulmonary fibrosis: the role of platelets in chronic changes induced by bleomycin. Journal of pharmacological and toxicological methods, 109, [107057]. https://doi.org/10.1016/j.vascn.2021.107057
6. Shah, S. A., Kanabar, V., Riffo-Vasquez, Y., Mohamed, Z., Cleary, S. J., Corrigan, C., James, A. L., Elliott, J. G., Shute, J. K., Page, C. P., & Pitchford, S. C.(2021). Platelets Independently Recruit into Asthmatic Lungs and Models of Allergic Inflammation via CCR3. American Journal of Respiratory Cell and Molecular Biology, 64(5), 557–568. https://doi.org/10.1165/rcmb.2020-0425OC
7. Arkless, K., Amison, R., Shankar-Hari, M., Page, C., & Pitchford, S.(2021). Stimulation of the Platelet P2Y(1) Receptor by Endogenous Agonists Leads to a Dichotomy in Platelet Function. British journal of pharmacology, 178(2), 381-382.
8. Manzo, G., Hind, C. K., Ferguson, P., Amison, R., Hodgson-Casson, A., Ciazynska, K., Weller, B., Clarke, M., Lam, C., Man, R., O'Shaughnessy, B., Clifford, M., Bui, T., Drake, A., Atkinson, A., Lam, J., Pitchford, S., Page, C., Phoenix, D., ... Mason, J.(2020). A Pleurocidin Analogue with Greater Conformational Flexibility, Enhanced Antimicrobial Potency and in vivo Therapeutic Efficacy. Communications Biology, 3(1), [697]. https://doi.org/10.1038/s42003-020-01420-3
9. Arnold, S., Shah, S. A., Cleary, S. J., O'shaughnessy, B. G., Amison, R. T., Arkless, K., Page, C. P., & Pitchford, S. C.(2020). Red Blood Cells Elicit Platelet-Dependent Neutrophil Recruitment into Lung Airspaces. Shock, 56(2). https://doi.org/10.1097/SHK.0000000000001705
10. Cleary, S. J., Pitchford, S. C., Amison, R. T., Carrington, R., Robaina Cabrera, C. L., Magnen, M., Looney, M. R., Gray, E., & Page, C. P.(2020). Animal models of mechanisms of SARS-CoV-2 infection and COVID-19 pathology. British Journal of Pharmacology, 177(21), 4851-4865. https://doi.org/10.1111/bph.15143

For the full list of publications for Dr Simon Pitchford, please visit the PURE Portal

---

Dr Bahijja Raimi-Abraham

1. Kok, X. W., Singh, A., & Raimi-Abraham, B. T.(2022). A Design Approach to Optimise Secure Remote Three-Dimensional (3D) Printing: A Proof-of-Concept Study towards Advancement in Telemedicine. Healthcare (Switzerland), 10(6), [1114]. https://doi.org/10.3390/healthcare10061114
2. Niaz, S., Forbes, B., & Raimi-Abraham, B. T.(2022). Exploiting Endocytosis for Non-Spherical Nanoparticle Cellular Uptake. Nanomanufacturing, 2(1), 1-16. https://doi.org/10.3390/nanomanufacturing2010001
3. Ellis, T., Eze, E., & Raimi-Abraham, B. T.(2021). Malaria and Cancer: a critical review on the established associations and new perspectives. Infectious Agents and Cancer, 16(1), [33]. https://doi.org/10.1186/s13027-021-00370-7
4. Al-Sahaf, Z., Raimi-Abraham, B., Licciardi, M., & de Mohac, L. M. (2020). Influence of Polyvinyl Alcohol (PVA) on PVA-Poly-N-hydroxyethyl-aspartamide (PVA-PHEA) Microcrystalline Solid Dispersion Films. AAPS PharmSciTech, 21(7), [267]. https://doi.org/10.1208/s12249-020-01811-z
5. Mašková, E., Kubová, K., Raimi-Abraham, B. T., Vllasaliu, D., Vohlídalová, E., Turánek, J., & Mašek, J. (2020). Hypromellose – A traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery. Journal of Controlled Release, 324, 695-727. https://doi.org/10.1016/j.jconrel.2020.05.045
6. De Mohac, L. M., Raimi-Abraham, B., Caruana, R., Gaetano, G., & Licciardi, M. (2020). Multicomponent solid dispersion a new generation of solid dispersion produced by spray-drying. Journal of drug delivery science and technology , 57, [101750]. https://doi.org/10.1016/j.jddst.2020.101750
7. Amin, P. D., Raimi-Abraham, B. T., Shah, D. S., & Gurram, S. (2020). Medicated topicals. In Remington: The Science and Practice of Pharmacy (pp. 381-393). Elsevier. https://doi.org/10.1016/B978-0-12-820007-0.00021-0
8. Allard, M., & Raimi-Abraham, B. T.(2019). Inclusion of pharmacy students in globalization of professional pharmacy practice. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 76(24), 2077-2079. https://doi.org/10.1093/ajhp/zxz242
9. Li Chew, S., de Mohac, L. M., & Raimi-Abraham, B. T.(2019). 3d-printed solid dispersion drug products. Pharmaceutics, 11(12), [672]. https://doi.org/10.3390/pharmaceutics11120672
10. Pazhanimala, S., Vllasaliu, D., & Abraham, B. T.(2019). Engineering Biomimetic Gelatin Based Nanostructures as Synthetic Substrates for Cell Culture. Applied Sciences (Switzerland), 9(8), [1583]. https://doi.org/10.3390/app9081583

For the full list of publications for Dr Bahijja Raimi-Abraham, please visit the PURE Portal

---

 

The academic staff members working within the Antimicrobial Theme have demonstrated remarkable success in securing substantial research funding from a variety of sources, including research councils, industry, charities, and overseas funding agencies. This funding has been instrumental in advancing their research programs and driving impactful discoveries. A snapshot of recent awards highlights the recognition of the Antimicrobial Theme and showcases its significant contributions to the field.

Professor Miraz Rahman

Project	Funder	Recipient	Dates
1. iCASE-Pheon: Explore efflux transporter-associated chemoresistance using a chemical biology approach and develop efflux resistant TOPO I inhibitors as ADC payloads.	Pheon Therapeutics	Rahman, M., Arnold, J.	1/10/2023 → 30/09/2027
2. Identifying the binding pocket of Cofilin-1, a novel drug target in Alzheimer’s disease	Alzheimer's Research UK	Parsons, R., Rahman, M.	1/11/2022 → 31/10/2023
3. Maplethorpe: Fighting tomorrow’s pandemic today: a multidisciplinary approach towards the design of ion channel inhibitors as antivirals for SARS-CoV-2 and wider coronaviruses.	UNIVERSITY OF LONDON	Rahman, M.	1/10/2022 → 30/09/2024
4. PROTAC-DJT: PROTAC degradation of OGA/OGT as a novel therapeutic strategy for the treatment of various human diseases and tool development	Daphne Jackson Trust	Rahman, M.	1/05/2022 → 30/04/2024
5. EBX-Antibiot: Developing a new class of antibiotics based on Efflux Resistant 4-oxoquinolizines for Multiple Drug-Resistant ESKAPE Pathogens	MRC Medical Research Council	Rahman, M., Amison, R.	1/04/2022 → 31/03/2025
6. Bacterial me: Bisbiguanide analogues as probes for assessing membrane barrier function in multidrug resistant Gram-negative bacteria.	PHE Public Health England	Rahman, M., Pitchford, S.	1/10/2021 → 30/09/2025
7. BBSRC TB Par: Characterizing the structure, function and drugability of tuberculosis proteins using Rv1127c as a Paradigm	BBSRC Biotechnology and Biological Sciences Research Council	Rahman, M.	1/04/2021 → 31/12/2023
8. Heme oxygenase-1 inhibition for the immunotherapy treatment of cancer	KHP R&D challenge fund	Arnold, J., Rahman, M., Spicer, J.	1/01/2021 → 31/12/2021
9. The role of the anaplerotic node in redox homeostasis and pathogenesis of Mycobacterium tuberculosis and its exploitation as a therapeutic target	BBSRC Biotechnology and Biological Sciences Research Council	Rahman, M.	1/03/2020 → 28/02/2023
10. Exploring bias in platelet P2Y1 receptor signalling: host defence versus haemostasis.	MRC Medical Research Council	Pitchford, S., Rahman, M., Page, C.	1/01/2020 → 31/12/2022
11. Development of new antibiofilm agents through repurposing of existing licensed drugs	National Biofilms Innovation Centre	Rahman, M.	1/11/2019 → 31/10/2021
12. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
13. A combined, chemical-microbiology approach to understand the function of novel antibiotic resistance determinant in Gram-negative bacteria	PHE Public Health England	Rahman, M.	1/10/2018 → 30/09/2022
14. Antimicrobial compounds; continued development	PHE Public Health England	Rahman, M.	1/04/2018 → 31/03/2019
15. Development of ARB-Linked 4-oxoquinolizine Antibiotics with Extended Spectrum Activity	Emergent BioSolutions	Rahman, M.	21/12/2017 → 31/12/2020
16. Evaluation of efflux pump inhibitors as adjunct therapies	PHE Public Health England	Rahman, M.	1/05/2017 → 30/09/2018
17. From lead candidate molecule to inhalable formulation: Can biocompatible nanoparticles provide a controlled-release platform suitable for delivery of a novel antibiotic compound to the lung?	University of London	Rahman, M., Woods, A.	1/01/2017 → 31/12/2018
18. Development of novel anti-tubercular compounds	PHE Public Health England	Rahman, M.	1/05/2016 → 28/02/2019
19. Development of rapid bacterial susceptibility platform	PHE Public Health England	Rahman, M.	1/05/2016 → 31/10/2017
20. Using chemical modification of a novel antimicrobial drug scaffold to reduce efflux from multidrug resistant Gram-negative ESKAPE pathogens	PHE Public Health England	Rahman, M., Page, C.	1/10/2015 → 30/09/2019
21. Development of fluoroindoloquinolones as broad spectrum bactericidal agents against multi-drug resistant bacteria	Guy's & St Thomas' Charity	Rahman, M.	1/08/2015 → 31/10/2015
22. Development of novel chemical scaffolds as chemical tools and antimicrobial agents against multidrug resistant Gram-negative pathogens	S.I.P. Winwin Import and Export Co.,Ltd	Rahman, M.	1/01/2015 → 31/12/2018
23. C8 Linked Pyrrolobenzodiazepines (PBDs) as Chemical Tools to Study Transcription Factor Mediated B-MYB Modulation in Breast Cancer	Guy's & St Thomas' Charity	Thurston, D., Rahman, M., Tutt, A.	1/10/2014 → 30/09/2015
24. The Development of Novel Highly-Cytotoxic MGBA (Minor Groove Binding Agent) Payloads for Antibody Drug Conjugates (ADCs).	Frederick Gardner Cottrell Foundation	Thurston, D., Rahman, M.	1/06/2014 → 31/05/2015
25. Extension of data package on novel antimicrobial agents	PHE Public Health England	Rahman, M.	1/04/2014 → 30/06/2018
26. Confidence in Concept 2013	MRC Medical Research Council	Blower, P., Henckaerts, E., Howell, S., Maccabe, J., Rahman, M., Rashid, T. et al.	1/03/2014 → 30/04/2016
27. Extension of data package on lead antimicrobial compounds	PHE Public Health England	Rahman, M.	1/05/2013 → 30/04/2015
28. Novel NF-kB transcription factor inhibitors for the treatment of haematological cancers	Worldwide Cancer Research	Thurston, D., Rahman, M.	1/01/2013 → 30/06/2016

 

Richard Amison

Project	Funder	Recipient	Dates
1. EBX-Antibiot: Developing a new class of antibiotics based on Efflux Resistant 4-oxoquinolizines for Multiple Drug-Resistant ESKAPE Pathogens	MRC Medical Research Council	Rahman, M., Amison, R.	1/04/2022 → 31/03/2025
2. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019

 

Ken Bruce

Project	Funder	Recipient	Dates
1. Biobanking bacteria from marine sources; a resource for novel bioactives	UNIVERSITY OF LONDON	Bruce, K., Forbes, B.	1/10/2022 → 30/09/2025
2. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
3. Radiolabelled siderophores for novel molecular imaging and treatment of vascular (endo)graft infections	MRC Medical Research Council	Abbate, V., Blower, P., Ma, M., Terry, S., Hider, R., Bruce, K. et al.	1/05/2019 → 31/01/2021
4. Defining adaptive processes in a model bacterial species by integrating proteomic and metabolomic analytical strategies	Ascend Diagnostics Ltd	Bruce, K., Mason, J.	1/10/2018 → 30/09/2022
5. How do mutations in pssA lead to antiseptic/antibiotic resistance in Pseudomanas aeruginosa	PHE Public Health England	Mason, J., Bruce, K.	1/10/2018 → 30/09/2022
6. Nottingham Molecular Pathology Node (NMPN) for Integrated Multi-platform Biomarker Research and Knowledge Transfer	MRC Medical Research Council	Bruce, K.	1/11/2017 → 31/03/2020
7. How do membrane active antibiotics influence microbiome dysbiosis?	PHE Public Health England	Mason, J., Tribe, R., Lorenz, C., Bruce, K.	1/10/2017 → 30/09/2021
8. Airway Infection in Bronchiectasis (Quorum sensing molecule (QSM) biomarkers for Pseudomonas aeruginosa)	NIHR National Institute For Health & Care Research	Bruce, K.	1/04/2017 → 31/03/2022
9. Improving the delivery of antibiotic care for CF patients	Anna Trust	Bruce, K.	1/08/2014 → 31/07/2015
10. The Gut-Liver Axis in Liver Failure Syndromes	ICS Intensive Care Society	Wendon, J., Bruce, K., Patel, V.	1/09/2013 → 31/01/2020
11. How do skin and gut microbiota relate to the risk of atopic eczema and food allergy in infancy?	British Skin Foundation	Flohr, C., Bruce, K., Lack, G., Perkin, M.	1/02/2013 → 31/10/2015
12. Design, synthesis and functional characterisation of delivery systems for Gram negative targeting Transcription Factor Decoy (TFD) antibiotics	Procarta Biosystems Ltd	Mason, J., Bansal, S., Bruce, K.	1/10/2010 → 30/09/2014
13. Microbial diversity in chronic lung allograft dysfunction	ROTRF Roche Organ Transplantation Research Foundation	Bruce, K., Rogers, G.	25/05/2010 → 24/05/2012
14. Cystic Fibrosis exacerbation analysis	Anna Trust	Bruce, K.	1/03/2010 → 30/09/2010
15. Biotreatment of oestrogen - a model for the biodegradation of pharmaceutical products and associated waste	ICUK Innovation China UK	Bruce, K., Lilley, A.	1/03/2009 → 31/07/2010
16. Anaerobic biological treatment of waste metal working fluids	ICUK Innovation China UK	Bruce, K., Lilley, A.	1/05/2009 → 30/04/2010
17. Understanding antimicrobial peptide mechanisms: a rationale for the improved design of antibiotics and vectors	MRC Medical Research Council	Mason, J., Bruce, K., Mitchell, G.	1/02/2010 → 31/01/2012
18. Microbiological assessment of prevention of colonisation of cystic fibrosis patients by Pseudomonas aeruginosa	SPARKS Sport Aiding Medical Research for Kids	Bruce, K.	1/11/2008 → 31/10/2011
19. Culture-independent analysis of bacteria	Royal Holloway, University of London	Bruce, K.	1/09/2008 → 31/08/2009
20. Microbiology of cystic fibrosis exacerbations	Anna Trust	Bruce, K.	1/07/2008 → 14/01/2011
21. The microbiological changes associated with cystic fibrosis exacerbations	University Hospital Southampton NHS Foundation Trust	Bruce, K., Connett, G.	1/04/2008 → 31/03/2010
22. Bacterial Infections in infectious exacerbation	Anna Trust	Bruce, K.	1/10/2006 → 30/04/2010
23. Molecular microbiological analysis of respiratory specimens sampled from infants with chronic lung disease of prematurity.	British Lung Foundation	Bruce, K., Connett, G., Puddy, V.	19/11/2007 → 21/01/2010
24. Funding for Dr Geraint Rogers.	University Hospital Southampton NHS Foundation Trust	Bruce, K.	1/03/2005 → 28/02/2006
25. The detection and treatment of Pseudomonas aeruginosa in the lungs of paediatric cystic fibrosis patients.	SPARKS Sport Aiding Medical Research for Kids	Bruce, K.	1/02/2005 → 31/01/2006
26. Emergence of Antibiotic Resistance	Royal Society	Bruce, K.	1/04/2001 → 30/09/2001
27. Molecular Characterisation of Integrons within Burkholderia cepacia	BSAC British Society for Antimicrobial Chemotherapy	Bruce, K.	1/04/2001 → 31/12/2003
28. Purchase of a Phoretix 1D Advanced V.5 &Viglen PC: An Analysis of Bacterial Community Profiles	University of London	Bruce, K.	1/04/2001 → 31/03/2002

 

Kourosh Ebrahimi

Project	Funder	Recipient	Dates
1. SEHAED: A novel High-Throughput Screening Method for Antiviral Enzyme Discovery (SEHAED)	Royal Society	Ebrahimi, K.	31/03/2023 → 30/03/2024
2. ECABSAMIM: Elucidating the Chemistry and Biology of A Radical-SAM Enzyme of The Innate Immune System	Royal Society	Ebrahimi, K.	12/08/2022 → 11/08/2024

 

Ben Forbes

Project	Funder	Recipient	Dates
1. BiaB Y2: Year 2 - Biofoundry-in-a-Box: Modular microfactories for powering the global RNA production networks	Wellcome Leap Inc.	Makatsoris, H., Ali, R., Forbes, B., Giacca, M.	1/03/2023 → 31/12/2023
2. Improving survival without bronchopulmonary dysplasia, and neurodevelopment in extreme preterm babies	MRC Medical Research Council	Victor, S., Edwards, D., Forbes, B., Greenough, A.	1/02/2023 → 31/01/2024
3. Advanced experimental & computational methods for optimising nasal drug delivery	Nanopharm Ltd	Forbes, B., Dreiss, C.	1/10/2022 → 30/09/2026
4. Biobanking bacteria from marine sources; a resource for novel bioactives	UNIVERSITY OF LONDON	Bruce, K., Forbes, B.	1/10/2022 → 30/09/2025
5. Inhaled PRP: Development of inhalable platelet-based therapy for treatment of acute lung injury	Biotherapy Services Ltd	Forbes, B., Pitchford, S.	1/10/2022 → 30/09/2026
6. BiaB: Biofoundry-in-a-Box: Modular microfactories for powering the global RNA production network	Wellcome Leap Inc.	Makatsoris, H., Ali, R., Forbes, B., Giacca, M.	1/01/2022 → 28/02/2023
7. Biologically-informed development of autologous platelet-based wound healing gels	Biotherapy Services Ltd	Forbes, B., Pitchford, S.	1/10/2021 → 30/09/2025
8. Translational Biopharmaceutics for Proteolysis Targeting Chimeras (PROTACs)	TSB Technology Strategy Board	Forbes, B.	1/03/2021 → 28/02/2024
9. Pharmacy practice role in the healthcare pathway for children and young people in the community	NPPG Neonatal and Paediatric Pharmacists Group	Rashed, A., Forbes, B.	1/07/2019 → 31/12/2022
10. Optimising biophysical interactions for lung retention of inhaled medicines	Vectura Ltd	Forbes, B., Page, C.	1/10/2018 → 30/09/2022
11. Biological modelling of inhalation cellular toxicity	Syngenta Ltd	Forbes, B., Mudway, I.	1/04/2017 → 31/12/2021
12. Mechanisms of sugar alcohol effects on respiratory membrane biophysics	Chiesi Ltd	Forbes, B., Harvey, R.	1/10/2016 → 30/09/2020
13. Differentiating alveolar macrophage responses to inhaled medicines	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Forbes, B., Collins, H., Dailey, L. A., Mudway, I., Page, C.	16/01/2015 → 30/11/2018
14. Development of an in vitro model for the dissolution of inhaled particles.	Aerosol Society	Forbes, B., Hauet Richer, N.	1/01/2015 → 30/06/2015
15. Development of a predictive model for the dissolution of inhaled particles	Intertek Melbourn	Forbes, B.	1/10/2014 → 30/09/2018
16. Is the delivery of adenosine as dry powder the answer to shortcomings in the bronchial challenge test?	University of London	Forbes, B., Lexmond, A., Page, C.	1/10/2014 → 30/09/2016
17. The biological basis of protein-based inhaled nanomedicines		Forbes, B., Dailey, L. A.	1/10/2014 → 30/09/2018
18. Differentiating alveloar macrophage responses to inhaled medicines	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Forbes, B., Collins, H., Dailey, L. A., Mudway, I., Page, C.	3/01/2014 → 2/07/2014
19. In vitro biopharmaceutical evaluation of novel respiratory medicines for airway disease	GSK GlaxoSmithKline Research & Development Ltd	Jones, S., Forbes, B., Page, C.	1/10/2013 → 30/09/2017
20. Mathematical modelling of bronchodilator compounds: target distribution - biological stimulus and response to Salbutamol	Daphne Jackson Trust	Forbes, B., academic, A.	8/04/2013 → 7/04/2015
21. A systems management approach for safe, patient-controlled analgesia in children	Health Foundation	Whittlesea, C., Forbes, B.	27/02/2013 → 26/11/2014
22. Smart Combination Respiratory Medicines for Optimal and Cost Effective Patient Benefit	TSB Technology Strategy Board	Forbes, B.	1/01/2013 → 30/06/2014
23. MOTIF - Microbicide Optimization Through Innovative Formulation for Vaginal and Rectal Delivery	EC European Commission	Kelly, C., Forbes, B.	1/10/2012 → 31/03/2016
24. The treatment of acute respiratory crisis using novel lung-targeting ion pairs	University of London	Forbes, B.	4/01/2011 → 3/01/2012
25. Design and evaluation of simulated human lung lining fluid	GSK GlaxoSmithKline Research & Development Ltd	Forbes, B., Mudway, I.	1/10/2010 → 30/09/2014
26. In vivo safety and particokinetics of inhaled nanomedicines	MRC Medical Research Council	Page, C., Dailey, L. A., Forbes, B., Jones, S., Spina, D.	1/06/2010 → 31/05/2013
27. Combined Highly Active Anti-Retroviral Microbicides (CHAARM)	EC European Commission	Kelly, C., Forbes, B.	1/01/2010 → 30/06/2015
28. Engineering multi-component delivery systems for the controlled transcellular transport of inhalation therapeutics	Pfizer Ltd	Martin, G., Murnane, D., Forbes, B.	1/09/2009 → 31/08/2013
29. Nanoparticle toxicokinetics in the nose: an assessment of risk	Unilever UK Central Resources Ltd	Forbes, B., Dailey, L. A.	1/10/2008 → 30/09/2011
30. 'Getting the drug to the worm' - the development of a new screening method for novel anthelminitic drugs	Sir Halley Stewart Trust	Forbes, B., Sanderson, L.	14/07/2008 → 13/10/2009
31. The role of transporters and metabolism in the disposition of inhaled salbutamol	University of London	Eriksson, A., Forbes, B.	1/01/2007 → 31/12/2007
32. Adaptation of the isolated perfused lung (ILP) technique for screening inhalation products [Cynthia Bosquillon Fellowship)	University of London	Forbes, B.	1/10/2005 → 30/09/2007
33. Analysis of the immune evasion mechanisms used by schistosomes penetrating human skin.	Sir Halley Stewart Trust	Brown, M., Forbes, B., Bartlett, A.	1/01/2005 → 31/08/2007
34. Towards a European PhD in Advanced Drug Delivery (GALENOS)	EC European Commission	Forbes, B.	1/10/2004 → 30/09/2008
35. Oral absorption of chemicals from complex matrices: in vitro prediction using factorial design	Unilever UK Central Resources Ltd	Brown, M., Forbes, B.	1/10/2003 → 30/09/2006
36. Calorimetric study into intestinal lipid digestion and drug absorption	EPSRC Engineering and Physical Sciences Research Council	Forbes, B.	23/02/2002 → 22/02/2003
37. Summer vacation scholarship	Wellcome Trust	Forbes, B.	4/06/2001 → 29/07/2001
38. Spray dried formulations for the pulmonary delivery of peptides and proteins.	EPSRC Engineering and Physical Sciences Research Council	Brown, M., Forbes, B., Martin, G.	14/02/2000 → 13/05/2003
39. Summer vacation scholarship	Wellcome Trust	Forbes, B.	7/06/1999 → 18/07/1999
40. Microbial resistance to biocides and antibiotics: the relationship.	Unilever UK Central Resources Ltd	Forbes, B.	1/01/1998 → 31/12/2000
41. Bacterial resistance to antimicrobial agents associated with stress survival.	Unilever UK Central Resources Ltd	Forbes, B.	1/10/1997 → 30/09/2000

 

Professor Stuart Jones

Project	Funder	Recipient	Dates
1. A multiplexed micro-suction biomarker extraction device to understand atopic eczema in babies	EPSRC Engineering and Physical Sciences Research Council	Jones, S., Flohr, C.	31/07/2023 → 30/07/2026
2. Understanding how environmental cutaneous exposure to peanut protein might cause food allergy in early life	Rosetrees Trust	Jones, S., Flohr, C., Santos, A.	19/04/2023 → 30/01/2026
3. Understanding how environmental cutaneous exposure to peanut protein might cause food allergy in early life	Stoneygate Trust	Jones, S., Flohr, C.	19/04/2023 → 30/01/2026
4. Preventing peanut allergy through improved understanding of the transcutaneous sensitisation route, novel food processing and skin care adaptations (TRANS-FOODS)	BBSRC Biotechnology and Biological Sciences Research Council	Flohr, C., Jones, S., Santos, A.	1/09/2022 → 31/08/2025
5. Capacity Building in Medicines Development Egypt	British Council	Jones, S., McClelland, G.	1/02/2022 → 31/12/2023
6. Developing barrier-enhancing creams to reduce transcutaneous exposure to peanut allergens in the early years of life	UNIVERSITY OF LONDON	Jones, S.	1/10/2021 → 30/09/2024
7. Understanding how mild skin hyperthermia influences vitamin D skin absorption and metabolism during nutritional supplementation	Curapel Ltd	Jones, S., Albed Alhnan, M.	1/10/2021 → 30/09/2025
8. Engineering Personalised Cutaneous Hypobaric Microchambers to Facilitate the Treatment of Local Infectious Diseases with Gaseous Signalling Molecules	EPSRC Engineering and Physical Sciences Research Council	Jones, S., Albed Alhnan, M.	1/06/2021 → 31/05/2023
9. Smart Nanomaterials for Protection and Remote-Controlled Delivery of Active Ingredients in Skin Care Products	RSS Royal Scientific Society	Al-Jamal, K., Jones, S.	4/04/2021 → 30/04/2023
10. Engineering a topical hypobaric patch: A needle-free solution for biopharmaceutical drug administration into the skin	EPSRC Engineering and Physical Sciences Research Council	Jones, S., Ameer-Beg, S.	1/10/2019 → 30/06/2023
11. Hypobaric hydrogen sulfide as a novel means to prevent food spoilage	Natures Way Foods Ltd	Jones, S.	1/04/2019 → 31/03/2023
12. Hypobaric cytokine profiling: a non-invasive means to characterise skin health during aging	Rosetrees Trust	Jones, S.	30/09/2017 → 29/09/2020
13. Multifunctional self-assembling ion-complexes	Johnson & Johnson	Jones, S., Hider, R.	1/11/2013 → 30/04/2017
14. In vitro biopharmaceutical evaluation of novel respiratory medicines for airway disease	GSK GlaxoSmithKline Research & Development Ltd	Jones, S., Forbes, B., Page, C.	1/10/2013 → 30/09/2017
15. The influence of barometric pressure changes upon membrane physiology and xenobiotic penetration	MedPharm Ltd	Jones, S.	1/10/2011 → 30/09/2015
16. A fundamental study to determine the difference in barrier properties of healthy and diseased nail in order to facilitate drug delivery	BBSRC Biotechnology and Biological Sciences Research Council	Jones, S.	1/10/2010 → 30/09/2013
17. In vivo safety and particokinetics of inhaled nanomedicines	MRC Medical Research Council	Page, C., Dailey, L. A., Forbes, B., Jones, S., Spina, D.	1/06/2010 → 31/05/2013
18. To increase understanding of depilatory cream efficacy and mode of action	TSB Technology Strategy Board	Jones, S.	24/05/2010 → 23/05/2012
	Reckitt Benckiser Group plc	Jones, S.	24/05/2010 → 23/05/2012
19. Microencapsulated nanoparticles to deliver novel drug ion pair combinations to the airways of the lung	MedPharm Ltd	Jones, S., Page, C.	1/08/2009 → 31/05/2014
20. Development of a novel self-assembly thermoregualtion osuics to enhance transdermal delivery	MedPharm Ltd	Brown, M., Jones, S.	1/10/2006 → 31/03/2010
	EPSRC Engineering and Physical Sciences Research Council	Brown, M., Jones, S.	1/10/2006 → 31/03/2010

 

Paul Long

Project	Funder	Recipient	Dates
1. Targeting Intracellular Vesicular Trafficking Using A Novel V-Atpase Inhibitor To Ameliorate Pathogenicity Of SARS-Cov-2 And Related Viral Pathogens	BSAC British Society for Antimicrobial Chemotherapy	Grigoriadis, A., Long, P., Malim, M.	1/11/2020 → 31/01/2023
2. Are endoparasitic cnidarians venomous animals? A pioneering study into an ancient lineage	Leverhulme Trust	Long, P.	2/05/2016 → 30/11/2019
3. Biosynthesis of mycosporine-like amino acid (MAA) photoprotectants follows a common genetic pathway in both free-living and symbiotic microorganisms	BBSRC Biotechnology and Biological Sciences Research Council	Long, P.	1/08/2010 → 31/07/2013

 

Professor James Mason

Project	Funder	Recipient	Dates
1. LIDo CASE 20: Multi-mode imaging to underpin a drug development pipeline for a new, peptide class of antibiotics	PHE Public Health England	Mason, J., Abbate, V.	1/10/2021 → 30/09/2025
2. In vitro model of viral encephalitis	Dstl Defence Science and Technology Laboratory	Preston-Kennedy, J., Mason, J.	26/07/2021 → 25/11/2022
3. Understanding phenotype and mechanisms of spontaneous preterm birth in sub-Saharan Africa (PRECISE-SPTB)	MRC Medical Research Council	Tribe, R., Falchi, M., Mason, J., Poston, L., von Dadelszen, P.	28/02/2021 → 27/02/2024
4. Development of antimicrobial peptides against Gram-negative antibiotic resistant pathogens	South African Medical Research Council	Mason, J., Lorenz, C.	1/01/2021 → 31/12/2023
5. Investigation of synergy in temporin antimicrobial peptides	LSBU London South Bank University	Mason, J.	1/08/2020 → 31/10/2020
6. Molecular dynamics enhanced hit-to-lead generation of therapeutic antimicrobial peptides	EPSRC IAA - Advancing Impact Award - Internal Fund	Lorenz, C., Mason, J.	1/07/2020 → 31/07/2021
7. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
8. Defining adaptive processes in a model bacterial species by integrating proteomic and metabolomic analytical strategies	Ascend Diagnostics Ltd	Bruce, K., Mason, J.	1/10/2018 → 30/09/2022
9. How do mutations in pssA lead to antiseptic/antibiotic resistance in Pseudomanas aeruginosa	PHE Public Health England	Mason, J., Bruce, K.	1/10/2018 → 30/09/2022
10. Exosomes in cervico-vaginal fluid of women at risk of preterm delivery	Action Medical Research	Tribe, R., Hezelgrave Elliott, N., Shennan, A., Mason, J.	1/04/2018 → 28/02/2022
11. Translation of new analogues of pleurocidin – new antibiotics for antibiotic resistant Acinetobacter baumannii wound infections	MRC Medical Research Council	Mason, J., Manzo, G.	8/01/2018 → 31/12/2018
12. How do membrane active antibiotics influence microbiome dysbiosis?	PHE Public Health England	Mason, J., Tribe, R., Lorenz, C., Bruce, K.	1/10/2017 → 30/09/2021
13. New analogues of pleurocidin – translation of a new antibiotic for antibiotic resistant Pseudomonas aeruginosa infections	KHP King's Health Partners	Mason, J., Page, C.	15/07/2017 → 14/01/2018
14. Amyloid and antimicrobial peptides: the membrane environment as the trigger for disease onset?	London South Bank University	Mason, J., Bansal, S., Harvey, R.	1/10/2014 → 30/09/2017
15. Development of novel genetic tools to engineer the CF Airway Microbiome.	Procarta Biosystems Ltd	Mason, J., Bansal, S.	1/10/2014 → 30/09/2018
16. Design, synthesis and functional characterisation of delivery systems for Gram negative targeting Transcription Factor Decoy (TFD) antibiotics	Procarta Biosystems Ltd	Mason, J., Bansal, S., Bruce, K.	1/10/2010 → 30/09/2014
17. Understanding antimicrobial peptide mechanisms: a rationale for the improved design of antibiotics and vectors	MRC Medical Research Council	Mason, J., Bruce, K., Mitchell, G.	1/02/2010 → 31/01/2012
18. Molecular mechanisms of antimicrobial peptides: phase changes induced in endotoxic bacterial liopolysaccharide	EPSRC Engineering and Physical Sciences Research Council	Harvey, R., Lawrence, M., Mason, J., Barlow, D.	1/02/2010 → 30/01/2014
19. Confirmational flexibility and toxicity of antibiotic and vector peptides	University of London Central Research Fund	Mason, J.	1/01/2008 → 30/09/2008
20. Value in People Award 2007/08	Wellcome Trust	Mason, J.	1/10/2007 → 30/09/2008
21. NIHR Biomedical Research Centre	NIHR National Institute For Health & Care Research	Afzali, B., Antoniou, M., Barker, J., Barratt, B., Bevan, S., Burchell, J. et al.	1/04/2007 → 31/03/2017
	DHSC Department of Health and Social Care	Afzali, B., Antoniou, M., Barker, J., Barratt, B., Bevan, S., Burchell, J. et al.	1/04/2007 → 31/03/2017

 

Clive Page

Project	Funder	Recipient	Dates
1. Investigating the in vitro and in vivo efficacy of combination therapies with the small-quinolone like compound HT61 against pulmonary infections with the MDR gram-negative ESKAPE pathogens P. aeruginosa, K. pneumoniae and A. baumannii	Helperby Therapeutics Group Limited	Amison, R., Page, C.	1/10/2022 → 30/09/2026
2. LIDo NIBSC P: Creation of modified heparins to probe platelet-endothelial glycocalyx interactions necessary for inflammation.	NIBSC National Institute for Biological Standards and Control	Pitchford, S., Page, C.	1/10/2021 → 30/09/2025
3. ACCORD2	UKRI UK Research and Innovation	Page, C.	1/05/2020 → 30/06/2021
4. Exploring bias in platelet P2Y1 receptor signalling: host defence versus haemostasis.	MRC Medical Research Council	Pitchford, S., Rahman, M., Page, C.	1/01/2020 → 31/12/2022
5. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
6. Optimising biophysical interactions for lung retention of inhaled medicines	Vectura Ltd	Forbes, B., Page, C.	1/10/2018 → 30/09/2022
7. Use of rapid combinatorial screening technology (CombiCult®) to create designer platelets optimized for tissue regeneration	Plasticell Ltd	Pitchford, S., Page, C.	1/10/2018 → 30/09/2022
8. New analogues of pleurocidin – translation of a new antibiotic for antibiotic resistant Pseudomonas aeruginosa infections	KHP King's Health Partners	Mason, J., Page, C.	15/07/2017 → 14/01/2018
9. To characterize the suitability of Combicult-derived megakaryocyte and platelet populations for transfusion medicine.	GLA Greater London Authority	Pitchford, S., Page, C.	1/07/2017 → 31/12/2018
10. Development of siderophore-antibiotic conjugates as an alternative drug delivery strategy to tackle multi-drug resistance in bacterial lung infections	EPSRC Engineering and Physical Sciences Research Council	Castagnolo, D., Page, C.	1/10/2016 → 31/03/2017
11. Using chemical modification of a novel antimicrobial drug scaffold to reduce efflux from multidrug resistant Gram-negative ESKAPE pathogens	PHE Public Health England	Rahman, M., Page, C.	1/10/2015 → 30/09/2019
12. Differentiating alveolar macrophage responses to inhaled medicines	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Forbes, B., Collins, H., Dailey, L. A., Mudway, I., Page, C.	16/01/2015 → 30/11/2018
13. Is the delivery of adenosine as dry powder the answer to shortcomings in the bronchial challenge test?	University of London	Forbes, B., Lexmond, A., Page, C.	1/10/2014 → 30/09/2016
14. Confidence in Concept 2013	MRC Medical Research Council	Blower, P., Henckaerts, E., Howell, S., Maccabe, J., Rahman, M., Rashid, T. et al.	1/03/2014 → 30/04/2016
15. Differentiating alveloar macrophage responses to inhaled medicines	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Forbes, B., Collins, H., Dailey, L. A., Mudway, I., Page, C.	3/01/2014 → 2/07/2014
16. In vitro biopharmaceutical evaluation of novel respiratory medicines for airway disease	GSK GlaxoSmithKline Research & Development Ltd	Jones, S., Forbes, B., Page, C.	1/10/2013 → 30/09/2017
17. Investigation of nanotoxicology and the development of new safety testing methodology in the study of inhaled nanoparticles	University of London	Dailey, L. A., Page, C.	1/09/2012 → 30/09/2013
18. Purinergic control of platelet mediated leukocyte recruitment	Pfizer Ltd	Page, C., Spina, D.	1/10/2010 → 30/09/2014
19. In vivo safety and particokinetics of inhaled nanomedicines	MRC Medical Research Council	Page, C., Dailey, L. A., Forbes, B., Jones, S., Spina, D.	1/06/2010 → 31/05/2013
20. Industrial Impact Fellowship in Drug Discovery	BBSRC Biotechnology and Biological Sciences Research Council	Christie, M., Page, C., Brain, S., Cox, H., Duty, S., Keeble, J. et al.	1/01/2010 → 31/12/2013
21. Microencapsulated nanoparticles to deliver novel drug ion pair combinations to the airways of the lung	MedPharm Ltd	Jones, S., Page, C.	1/08/2009 → 31/05/2014
22. The role of adhesion molecules and chemokins in platelet-mediated leukocyte recruitment	Pfizer Ltd	Page, C.	1/10/2007 → 30/09/2011
23. Research Collaboration	St George's, University of London	Page, C.	24/10/2004 → 23/10/2005
24. Novel Therapy for Asthma	DTI Department of Trade and Industry	Page, C.	1/02/2004 → 31/03/2005
25. Endogenous heparin from mast cells: a role in regulating inflammatory cell recruitment	Wellcome Trust	Page, C.	11/10/2003 → 10/10/2005
26. Study of the effect of Chaperonin 60.1 in the respiratory system.	St George's, University of London	Page, C.	1/01/2003 → 31/12/2003
27. Roles of protease-activated receptor-2 (PAR2) in airway hyperresponsiveness	Wellcome Trust	Moffatt, J., Page, C.	21/07/2002 → 20/07/2004
28. Beta-adrencoetor-mediated nitric oxide generation in platelets in health and diabetes	Guy's & St Thomas' Charity	Ferro, A., Page, C.	1/07/2002 → 31/12/2003
29. Image analysis in the investigation of the role of inflammation in the pathogenesis of asthma	MRC Medical Research Council	Page, C., O'Connor, B., Spina, D.	1/01/1999 → 30/06/1999
30. Marine biofouling surface active proteoglycan secretions from marine invertebrates and their role in modulating data	NERC Natural Environment Research Council	Page, C.	1/02/1997 → 31/01/1999
31. Neonatal sensitisation to airborne allergens	MRC Medical Research Council	Page, C.	1/06/1995 → 31/05/1997

 

Dr Barry Panaretou

Project	Funder	Recipient	Dates
1. Combining yeast chemical genetics and AI to enable efficient identification of molecules from plants and fungi with cell inhibitory modes-of-action relevant to human health	Royal Botanic Gardens, Kew	Panaretou, B.	1/10/2022 → 30/09/2026
2. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
3. Characterising the mechanism that controls resistance to antifungal agents mediated by a signalling cascade	Nuffield Foundation	Panaretou, B.	8/07/2009 → 7/09/2009
4. Mutagenesis of openreading frames in yeast	British Council	Panaretou, B.	2/07/2007 → 1/09/2007
5. Phosphoinositide signalling and fungal cell wall integrity: investigating the essential role of the conserved protein Ypp1	BBSRC Biotechnology and Biological Sciences Research Council	Panaretou, B.	10/09/2007 → 9/03/2011
6. Cloning and expression of yeast genes involved in signalling pathways	British Council	Panaretou, B.	3/07/2006 → 2/09/2006
7. Novel system for producing membrane proteins in bacteria	Heptagon Proof of Concept Fund	Barlow, D., Lawrence, M., Harvey, R., Marsh, P., Panaretou, B.	1/02/2005 → 30/11/2005
8. Membrane Protein Expression.	Principal's Discretionary Fund	Barlow, D., Lawrence, M., Marsh, P., Panaretou, B.	1/09/2004 → 31/01/2005
9. Functional characterisation of an essential conserved cell cycle gene involved in the metaphase to anaphase transition	BBSRC Biotechnology and Biological Sciences Research Council	Panaretou, B.	1/10/2004 → 30/09/2007
10. Iaste UK Trainee	British Council	Panaretou, B.	1/07/2003 → 30/09/2003
11. Functional Analysis of Aha1, a Highly Conserved Protein that Activates the ATPase of the Essential Chaperone Hsp90	Wellcome Trust	Panaretou, B.	1/10/2002 → 30/09/2005
12. Genomic analysis of iron metabolism	Royal Society	Panaretou, B.	1/05/2002 → 30/04/2003
13. Construction of tagged alleles and for positive selection of cells bearing targeted gene deletions: a functional analysis of chaperone mediated protein folding	University of London	Panaretou, B.	1/07/2001 → 31/07/2005
14. Use of conditional mutants to isolate protein sub-complexes from the Hsp90 cycle: a chaperone cycle essential for cell viability	Nuffield Foundation	Panaretou, B.	1/03/2001 → 31/05/2003

 

Dr Simon Pitchford

Project	Funder	Recipient	Dates
1. Inhaled PRP: Development of inhalable platelet-based therapy for treatment of acute lung injury	Biotherapy Services Ltd	Forbes, B., Pitchford, S.	1/10/2022 → 30/09/2026
2. Biologically-informed development of autologous platelet-based wound healing gels	Biotherapy Services Ltd	Forbes, B., Pitchford, S.	1/10/2021 → 30/09/2025
3. Bacterial me: Bisbiguanide analogues as probes for assessing membrane barrier function in multidrug resistant Gram-negative bacteria.	PHE Public Health England	Rahman, M., Pitchford, S.	1/10/2021 → 30/09/2025
4. LIDo NIBSC P: Creation of modified heparins to probe platelet-endothelial glycocalyx interactions necessary for inflammation.	NIBSC National Institute for Biological Standards and Control	Pitchford, S., Page, C.	1/10/2021 → 30/09/2025
5. Exploring bias in platelet P2Y1 receptor signalling: host defence versus haemostasis.	MRC Medical Research Council	Pitchford, S., Rahman, M., Page, C.	1/01/2020 → 31/12/2022
6. Assessing the relevance of Galleria mellonella to antibiotic drug discovery for pulmonary infections	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Mason, J., Amison, R., Page, C., Pitchford, S., Bruce, K., Rahman, M. et al.	3/06/2019 → 2/12/2019
7. Use of rapid combinatorial screening technology (CombiCult®) to create designer platelets optimized for tissue regeneration	Plasticell Ltd	Pitchford, S., Page, C.	1/10/2018 → 30/09/2022
8. To characterize the suitability of Combicult-derived megakaryocyte and platelet populations for transfusion medicine.	GLA Greater London Authority	Pitchford, S., Page, C.	1/07/2017 → 31/12/2018
9. Real time monitoring techniques and simplistic platelet assays to reduce and refine animal use in cardiovascular and respiratory biomedical research	NC3Rs National Centre for the Replacement, Refinement and Reduction of Animals in Research	Pitchford, S.	1/10/2014 → 30/09/2016

 

Dr Bahijja Raimi-Abraham

Project	Funder	Recipient	Dates
1. Computer-aided Engineering of Biomimetic Intestinal Scaffolds To Combat Intestinal Failure in Paediatrics	Royal Society	Raimi-Abraham, B.	21/03/2022 → 20/03/2023
2. Endocytosis of emerging nanomedicines: Understanding the influence of shape of 3D nanoprinted soft matter materials	BASF SE	Raimi-Abraham, B.	1/10/2019 → 30/09/2023